Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.59 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.59 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.59 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.59 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.59 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.59 |
| ▸ | KYNU | Q16719 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | CTSL | P07711 | 2/20 | 0.56 |
| ▸ | CTSS | P25774 | 1/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | TLR2 | O60603 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.52 |
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8447229 | 1.00 | SIRT2 (0.59) | SIRT2SIRT1SIRT3PRSS1PRSS2 | |
| Hydrochloric Acid SCHEMBL6236103 | 0.99 | SIRT2 (0.58) | SIRT2SIRT1SIRT3PRSS1PRSS2 | |
| Hydrochloric Acid SCHEMBL6236109 | 0.99 | SIRT2 (0.58) | SIRT2SIRT1SIRT3PRSS1PRSS2 | |
| SCHEMBL6477219 | 0.96 | SIRT2 (0.61) | SIRT2SIRT1SIRT3PRSS1PRSS2 | |
| SCHEMBL1840309 | 0.96 | SIRT2 (0.61) | SIRT2SIRT1SIRT3PRSS1PRSS2 | |
| SCHEMBL1840311 | 0.96 | SIRT2 (0.61) | SIRT2SIRT1SIRT3PRSS1PRSS2 | |
| Hydrochloric Acid SCHEMBL6528872 | 0.95 | SIRT2 (0.60) | SIRT2SIRT1SIRT3PRSS1PRSS2 | |
| Hydrochloric Acid SCHEMBL3952159 | 0.95 | SIRT2 (0.60) | SIRT2SIRT1SIRT3PRSS1PRSS2 | |
| Hydrochloric Acid SCHEMBL3952162 | 0.95 | SIRT2 (0.60) | SIRT2SIRT1SIRT3PRSS1PRSS2 | |
| SCHEMBL22029461 | 0.92 | KYNU (0.60) | SIRT2SIRT1SIRT3KYNUALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115561-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| EP-4469441-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | Parion Sciences, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146892-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20160213742-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160213742-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| WO-2015035102-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| US-7312218-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB CO. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070099922-A1 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | HAN WEI | 2007-05-03 | — | — | US | disclosed |
| US-7169795-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| EP-0543997-B1 | DERIVATIVES OF METHOTREXATE WITH ANTIRHEUMATIC ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1999-12-08 | — | — | EP | disclosed |
| EP-0885186-A1 | AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND PROCESSES FOR PREPARING THEM | Dr. Karl Thomae GmbH (DE) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997019911-A1 | AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND PROCESSES FOR PREPARING THEM | DR. KARL THOMAE GMBH (DE) | 1997-06-05 | — | — | WO | disclosed |
| EP-0324659-B1 | Enzymatic process for producing immunomodulating pentapeptides and intermediates for use in the process | CARLBIOTECH LTD AS (DK) | 1995-08-02 | — | — | EP | disclosed |
| EP-0543997-A1 | NOVEL METHOTREXATE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 1993-06-02 | — | — | EP | disclosed |
| WO-1989006656-A1 | ENZYMATIC PROCESS FOR PRODUCING IMMUNOMODULATING PENTAPEPTIDES AND INTERMEDIATES FOR USE IN THE PROCESS | CARLSBERG BIOTECHNOLOGY LTD. A/S (DK) | 1989-07-27 | — | — | WO | disclosed |
| EP-0324659-A2 | Enzymatic process for producing immunomodulating pentapeptides and intermediates for use in the process | CARLBIOTECH LTD. A/S (DK) | 1989-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115561-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1G | SIRT2 3063/4885SIRT1 1765/4885SIRT3 1298/4885 |
| US-20070099922-A1 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | TFPI, F12, F5 | SIRT2 1162/4885SIRT1 569/4885SIRT3 784/4885 |
| US-20160213742-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | FPR1, FPR3, FPR2 | SIRT2 4454/4885SIRT1 3816/4885SIRT3 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.